Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

Leveraged Daily Exposure to Cresco Labs

Dec 22, 2025 | Team Kalkine
Leveraged Daily Exposure to Cresco Labs
Image source: Shutterstock

The Tradr 2X Long CLS Daily ETF seeks to provide twice the daily return of Cresco Labs’ equity performance through the use of derivatives such as total return swaps and other financial instruments, rather than holding the stock directly.

Because leverage is reset daily, performance over periods longer than one trading session can diverge materially from 2x the cumulative return of CLS due to daily compounding effects.

How the Leverage Works

Because the ETF is 2x leveraged on a daily basis:

  • A +1% daily move in CLS is designed to result in an approximately +2% move in the ETF (before fees).
  • A −1% daily move in CLS would generally translate into an approximately −2% move in the ETF.

Over multiple days, returns can vary significantly depending on volatility and the path of price movements, not just the net direction.

Exposure to a High-Beta, Policy-Sensitive Stock

Cresco Labs operates in the U.S. cannabis sector, an industry heavily influenced by:

  • U.S. federal and state-level regulatory developments
  • Cannabis rescheduling discussions
  • SAFE Banking Act progress
  • Earnings results and margin trends
  • Capital market access and investor risk appetite

As a result, CLS often exhibits high daily volatility, which directly impacts the performance—and risk profile—of a 2x leveraged ETF tracking it.

The Tradr 2X Long CLS Daily ETF magnifies both upside and downside moves, making it particularly sensitive to:

  • Earnings announcements
  • Regulatory headlines
  • Broad cannabis sector momentum

Who Should Consider Tradr 2X Long CLS Daily ETF?

This ETF is not designed for buy-and-hold investors. It is best suited for experienced traders who understand leveraged products and monitor positions actively.

Common Use Cases

1.Short-Term Tactical Trading:

Traders with a high-conviction, short-term bullish view on Cresco Labs—perhaps around earnings, regulatory news, or sector momentum—may use the ETF to amplify returns without using margin directly.

2. Event-Driven Positioning:

Investors anticipating near-term catalysts such as earnings surprises, legalization headlines, or sector-wide rallies may deploy the ETF for brief holding periods to express that view.

Key Risks and Strategic Considerations

Before using the Tradr 2X Long CLS Daily ETF, investors should carefully consider:

  • Leverage & Compounding Risk: Returns over periods longer than one day can deviate sharply from 2x CLS performance, especially in volatile or sideways markets.
  • Single-Stock Risk: Exposure is concentrated in one company, increasing idiosyncratic risk versus diversified cannabis ETFs.
  • Sector Volatility: Cannabis equities are among the most volatile segments of the equity market.
  • Daily Reset Risk: The ETF is intended for daily trading, not long-term investment.
  • Higher Expense Ratio & Financing Costs: Leveraged ETFs generally carry higher costs than traditional equity ETFs.

Price Chart Technical Summary

Conclusion

The Tradr 2X Long CLS Daily ETF is a high-risk, high-reward tactical instrument designed to deliver twice the DAILY performance of Cresco Labs. It is best used by active traders seeking short-term exposure to a volatile, catalyst-driven cannabis stock.

While the ETF can generate outsized gains during strong bullish moves in CLS, it also carries meaningful downside risk and is unsuitable for long-term holding. Proper position sizing, disciplined risk management, and a clear understanding of leveraged ETF mechanics are essential when trading this product. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is December 22, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings.

Note 4: ‘Kalkine reports are prepared based on the prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.


Disclaimer-

This report has been issued by Kalkine Limited (Company number 07903332), a private limited company, incorporated in England and Wales ("Kalkine”). Kalkine.co.uk and associated pages are published by Kalkine. Kalkine is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites.  All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain non personalized recommendations to invest in securities and other financial products.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Please also read our Terms & Conditions for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Limited, an affiliate of Kalkine, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this report.

Past performance is not a reliable indicator of future performance.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions